Ilya Pharma, an innovative Swedish pharmaceutical company, develops drug candidates for PoC in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins. The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences.
Ilya Pharma
Developing the next-generation biological drugs for treating wounds in skin and mucosa.
